Sign In
Buy PASG
$4.47
-0.0200 (-0.445%)
At Close: Jul 31, 2026
Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
07:30am, Wednesday, 31'st Jan 2024
PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,
7 Nano-Cap Stocks That Pack a Serious Punch for Their Weight
10:14pm, Monday, 25'th Dec 2023
Playing in the field of nano-cap stocks is similar to the concept of stealing bases. In a tight baseball game, every advantage counts.
Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
07:00am, Wednesday, 20'th Dec 2023
PHILADELPHIA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
04:30pm, Friday, 17'th Nov 2023
PHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
07:00am, Monday, 13'th Nov 2023
PHILADELPHIA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (
Passage Bio to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference
07:00am, Monday, 30'th Oct 2023
PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 20'th Oct 2023
PHILADELPHIA, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (
Passage Bio to Present at Chardan's 7th Annual Genetic Medicines Conference
07:00am, Monday, 25'th Sep 2023
PHILADELPHIA, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
07:15am, Monday, 07'th Aug 2023
PHILADELPHIA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (
Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study
07:00am, Monday, 07'th Aug 2023
PHILADELPHIA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (
Passage Bio to Participate in Upcoming Investor Conferences
07:00am, Tuesday, 01'st Aug 2023
PHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (
Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors
07:00am, Monday, 31'st Jul 2023
PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (
Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference
07:00am, Monday, 05'th Jun 2023
PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (
Passage Bio to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
07:00am, Monday, 17'th Apr 2023
PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system
Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
07:00am, Monday, 27'th Mar 2023
PHILADELPHIA, March 27, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system
